Scott Dunseth Myers is Director of Zentalis Pharmaceuticals, Inc.. Currently has a direct ownership of 281,192 shares of ZNTL, which is worth approximately $413,352. The most recent transaction as insider was on Apr 30, 2025, when has been sold 21,000 shares (Common Stock) at a price of $1.4 per share, resulting in proceeds of $29,399. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 281K
8.07% 3M change
n/a 12M change
Total Value Held $413,352

Scott Dunseth Myers Transaction History

Date Transaction Value Shares Traded Shares Held Form
Apr 30 2025
BUY
Open market or private purchase
$29,399 $1.4 p/Share
21,000 Added 6.95%
281,192 Common Stock
Nov 13 2024
BUY
Grant, award, or other acquisition
-
260,192 Added 50.0%
260,192 Common Stock

Also insider at

AMAG
AMAG PHARMACEUTICALS, INC.
SELB
SELECTA BIOSCIENCES INC Healthcare
HARP
Harpoon Therapeutics, Inc. Healthcare
DVAX
DYNAVAX TECHNOLOGIES CORP Healthcare
VRDN
Viridian Therapeutics, Inc.\DE Healthcare
SDM

Scott Dunseth Myers

Director
Emeryville, CA

Track Institutional and Insider Activities on ZNTL

Follow Zentalis Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ZNTL shares.

Notify only if

Insider Trading

Get notified when an Zentalis Pharmaceuticals, Inc. insider buys or sells ZNTL shares.

Notify only if

News

Receive news related to Zentalis Pharmaceuticals, Inc.

Track Activities on ZNTL